The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wildtype and -mutant lower grade gliomas
野生型
突变体
生物
遗传学
基因
作者
Connor J. Kinslow,Soumyajit Roy,Fabio Iwamoto,Paul D. Brown,David DeStephano,Peter Canoll,Summer S Qureshi,Matthew Gallito,Michael B. Sisti,Jeffrey N. Bruce,David P. Horowitz,Lisa A. Kachnic,Alfred I. Neugut,James B. Yu,Minesh P. Mehta,Simon K. Cheng,Tony J. C. Wang
出处
期刊:Neuro-oncology [Oxford University Press] 日期:2024-06-29
IDH-wildtype (-wt) status is a pre-requisite for the diagnosis of glioblastoma (GBM); however, IDH-wt gliomas with low grade or anaplastic morphology have historically been excluded from GBM trials and may represent a distinct prognostic entity. While alkylating agent chemotherapy improves overall survival (OS) and progression-free survival (PFS) for IDH-wt GBM and also IDH-mutant gliomas, irrespective of grade, the benefit for IDH-wt diffuse histologic lower grade gliomas is unclear.